ZyVersa Therapeutics, Inc. [Rocket]

Overview

ZyVersa Therapeutics, Inc.

Add to portfolio

Recent News + Filings (All items)

Date Filed	Type	Description
10/05/2023	S-1/A	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
08/21/2023	10-Q	Quarterly Report for the period ended June 30, 2023
08/18/2023	8-K	Quarterly results
08/15/2023	NT 10-Q	Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
08/03/2023	4	INCON Co., Ltd. (10% Owner) has filed a Form 4 on ZyVersa Therapeutics, Inc.
07/26/2023	424B4	Form 424B4 - Prospectus [Rule 424(b)(4)]:
07/26/2023	8-K	Quarterly results

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20
Revenues	0.0	0.0
Cost of goods sold	0.0	0.0
Gross profit	0.0	0.0
Research and development	2.1	6.5
General and administrative	5.6	5.4
EBIT	-7.7	-11.8
Pre-tax income	-8.1	-12.7
Income taxes	0.0	0.0
Tax rate	0.0%	0.0%
Net income	-8.1	-12.7

Diluted EPS	($0.33)	($0.54)
Shares outstanding (diluted)	24.2	23.6

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy